22 results on '"Te Boekhorst PAW"'
Search Results
2. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease.
- Author
-
Jalink M, Jacobs CF, Khwaja J, Evers D, Bruggeman C, Fattizzo B, Michel M, Crickx E, Hill QA, Jaeger U, Kater AP, Mäkelburg ABU, Breedijk A, Te Boekhorst PAW, Hoeks MPA, de Haas M, D'Sa S, and Vos JMI
- Subjects
- Humans, Female, Male, Middle Aged, Adult, Aged, Retrospective Studies, Treatment Outcome, ADP-ribosyl Cyclase 1 antagonists & inhibitors, Anemia, Hemolytic, Autoimmune drug therapy, Antibodies, Monoclonal therapeutic use
- Abstract
Abstract: Autoimmune hemolytic anemia (AIHA) is a rare autoantibody-mediated disease. For steroid and/or rituximab-refractory AIHA, there is no consensus on optimal treatment. Daratumumab, a monoclonal antibody targeting CD38, could be beneficial by suppression of CD38+ plasma cells and thus autoantibody secretion. In addition, because CD38 is also expressed by activated T cells, daratumumab may also act via immunomodulatory effects. We evaluated the efficacy and safety of daratumumab monotherapy in an international retrospective study including 19 adult patients with heavily pretreated refractory AIHA. In warm AIHA (wAIHA, n = 12), overall response was 50% with a median response duration of 5.5 months (range, 2-12), including ongoing response in 2 patients after 6 and 12 months. Of 6 nonresponders, 4 had Evans syndrome. In cold AIHA (cAIHA, n = 7) overall hemoglobin (Hb) response was 57%, with ongoing response in 3 of 7 patients. One additional patient with nonanemic cAIHA was treated for severe acrocyanosis and reached a clinical acrocyanosis response as well as a Hb increase. Of 6 patients with cAIHA with acrocyanosis, 4 had improved symptoms after daratumumab treatment. In 2 patients with wAIHA treated with daratumumab, in whom we prospectively collected blood samples, we found complete CD38+ T-cell depletion after daratumumab, as well as altered T-cell subset differentiation and a severely diminished capacity for cell activation and proliferation. Reappearance of CD38+ T cells coincided with disease relapse in 1 patient. In conclusion, our data show that daratumumab therapy may be a treatment option for refractory AIHA. The observed immunomodulatory effects that may contribute to the clinical response deserve further exploration., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
3. Comprehensive characterization of circulating tumor cells and cell-free DNA in patients with metastatic melanoma.
- Author
-
Bos MK, Kraan J, Starmans MPA, Helmijr JCA, Verschoor N, De Jonge MJA, Joosse A, van der Veldt AAM, Te Boekhorst PAW, Martens JWM, Sleijfer S, and Wilting SM
- Abstract
Advances in therapeutic approaches for melanoma urge the need for biomarkers that can identify patients at risk for recurrence and to guide treatment. The potential use of liquid biopsies in identifying biomarkers is increasingly being recognized. Here, we present a head-to-head comparison of several techniques to analyze circulating tumor cells (CTCs) and cell-free DNA (cfDNA) in 20 patients with metastatic melanoma. In this study, we investigated whether diagnostic leukapheresis (DLA) combined with multimarker flow cytometry (FCM) increased the detection of CTCs in blood compared to the CellSearch platform. Additionally, we characterized cfDNA at the level of somatic mutations, extent of aneuploidy and genome-wide DNA methylation. Both CTCs and cfDNA measures were compared to tumor markers and extracranial tumor burden on radiological imaging. Compared to the CellSearch method applied on peripheral blood, DLA combined with FCM increased the proportion of patients with detectable CTCs from 35% to 70% (P = 0.06). However, the median percentage of cells that could be recovered by the DLA procedure was 29%. Alternatively, cfDNA mutation and methylation analysis detected tumor load in the majority of patients (90% and 93% of samples successfully analyzed, respectively). The aneuploidy score was positive in 35% of all patients. From all tumor measurements in blood, lactate dehydrogenase (LDH) levels were significantly correlated to variant allele frequency (P = 0.004). Furthermore, the presence of CTCs in DLA was associated with tumor burden (P < 0.001), whereas the presence of CTCs in peripheral blood was associated with number of lesions on radiological imaging (P < 0.001). In conclusion, DLA tended to increase the proportion of patients with detectable CTCs but was also associated with low recovery. Both cfDNA and CTCs were correlated with clinical parameters such as LDH levels and extracranial tumor burden., (© 2024 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
- Published
- 2024
- Full Text
- View/download PDF
4. Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.
- Author
-
van de Loosdrecht AA, Cremers EMP, Alhan C, Duetz C, In 't Hout FEM, Visser-Wisselaar HA, Chitu DA, Verbrugge A, Cunha SM, Ossenkoppele GJ, Janssen JJWM, Klein SK, Vellenga E, Huls GA, Muus P, Langemeijer SMC, de Greef GE, Te Boekhorst PAW, Raaijmakers MHG, van Marwijk Kooy M, Legdeur MC, Wegman JJ, Deenik W, de Weerdt O, van Maanen-Lamme TM, Jobse P, van Kampen RJW, Beeker A, Wijermans PW, Biemond BJ, Tanis BC, van Esser JWJ, Schaar CG, Noordzij-Nooteboom HS, Jacobs EMG, de Graaf AO, Jongen-Lavrencic M, Stevens-Kroef MJPL, Westers TM, and Jansen JH
- Subjects
- Humans, Lenalidomide pharmacology, Erythropoiesis, Granulocyte Colony-Stimulating Factor pharmacology, Chromosome Deletion, Chromosomes, Human, Pair 5 genetics, Treatment Outcome, Hematinics pharmacology, Myelodysplastic Syndromes drug therapy, Myelodysplastic Syndromes genetics
- Abstract
A randomized phase-II study was performed in low/int-1 risk MDS (IPSS) to study efficacy and safety of lenalidomide without (arm A) or with (arm B) ESA/G-CSF. In arm B, patients without erythroid response (HI-E) after 4 cycles received ESA; G-CSF was added if no HI-E was obtained by cycle 9. HI-E served as primary endpoint. Flow cytometry and next-generation sequencing were performed to identify predictors of response. The final evaluation comprised 184 patients; 84% non-del(5q), 16% isolated del(5q); median follow-up: 70.7 months. In arm A and B, 39 and 41% of patients achieved HI-E; median time-to-HI-E: 3.2 months for both arms, median duration of-HI-E: 9.8 months. HI-E was significantly lower in non-del(5q) vs. del(5q): 32% vs. 80%. The same accounted for transfusion independency-at-week 24 (16% vs. 67%), but similar in both arms. Apart from presence of del(5q), high percentages of bone marrow lymphocytes and progenitor B-cells, a low number of mutations, absence of ring sideroblasts, and SF3B1 mutations predicted HI-E. In conclusion, lenalidomide induced HI-E in patients with non-del(5q) and del(5q) MDS without additional effect of ESA/G-CSF. The identified predictors of response may guide application of lenalidomide in lower-risk MDS in the era of precision medicine. (EudraCT 2008-002195-10)., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
5. Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
- Author
-
Theocharides A, Gisslinger H, De Stefano V, Accurso V, Iurlo A, Devos T, Egyed M, Lippert E, Delgado RG, Cantoni N, Dahm AEA, Sotiropoulos D, Houtsma E, Smyth A, Iqbal A, Di Matteo P, Zuurman M, and Te Boekhorst PAW
- Subjects
- Humans, Middle Aged, Nitriles, Pyrimidines therapeutic use, Hydroxyurea adverse effects, Polycythemia Vera diagnosis, Polycythemia Vera drug therapy, Pyrazoles
- Abstract
Background: Hydroxyurea (HU) is a commonly used first-line treatment in patients with polycythemia vera (PV). However, approximately 15%-24% of PV patients report intolerance and resistance to HU., Methods: This phase IV, European, real-world, observational study assessed the efficacy and safety of ruxolitinib in PV patients who were resistant and/or intolerant to HU, with a 24-month follow-up. The primary objective was to describe the profile and disease burden of PV patients., Results: In the 350 enrolled patients, 70% were >60 years old. Most patients (59.4%) had received ≥1 phlebotomy in the 12 months prior to the first dose of ruxolitinib. Overall, 68.2% of patients achieved hematocrit control with 92.3% patients having hematocrit <45% and 35.4% achieved hematologic remission at month 24. 85.1% of patients had no phlebotomies during the study. Treatment-related adverse events were reported in 54.3% of patients and the most common event was anemia (22.6%). Of the 10 reported deaths, two were suspected to be study drug-related., Conclusion: This study demonstrates that ruxolitinib treatment in PV maintains durable hematocrit control with a decrease in the number of phlebotomies in the majority of patients and was generally well tolerated., (© 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
6. Measuring Mitochondrial Oxygen Tension during Red Blood Cell Transfusion in Chronic Anemia Patients: A Pilot Study.
- Author
-
Ubbink R, Streng LWJM, Raat NJH, Harms FA, Te Boekhorst PAW, Stolker RJ, and Mik EG
- Abstract
In light of the associated risks, the question has been raised whether the decision to give a blood transfusion should solely be based on the hemoglobin level. As mitochondria are the final destination of oxygen transport, mitochondrial parameters are suggested to be of added value. The aims of this pilot study were to investigate the effect of a red blood cell transfusion on mitochondrial oxygenation as measured by the COMET device in chronic anemia patients and to explore the clinical usability of the COMET monitor in blood transfusion treatments, especially the feasibility of performing measurements in an outpatient setting. To correct the effect of volume load on mitochondrial oxygenation, a red blood cell transfusion and a saline infusion were given in random order. In total, 21 patients were included, and this resulted in 31 observations. If patients participated twice, the order of infusion was reversed. In both the measurements wherein a blood transfusion was given first and wherein 500 mL of 0.9% saline was given first, the median mitochondrial oxygen tension decreased after red blood cell transfusion. The results of this study have strengthened the need for further research into the effect of blood transfusion tissue oxygenation and the potential role of mitochondrial parameters herein.
- Published
- 2023
- Full Text
- View/download PDF
7. Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial.
- Author
-
Huygens S, Hofsink Q, Nijhof IS, Goorhuis A, Kater AP, Te Boekhorst PAW, Swaneveld F, Novotný VMJ, Bogers S, Welkers MRA, Papageorgiou G, Rijnders BJ, and Heijmans J
- Subjects
- Humans, SARS-CoV-2, Immunoglobulins, Intravenous therapeutic use, Treatment Outcome, COVID-19 Serotherapy, Immunization, Passive adverse effects, COVID-19
- Abstract
Background: The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients., Methods: Patients were randomly assigned to receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies., Results: Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 of 8 (88%) in the IVIG control group (P = .015, Fisher's exact test)., Conclusions: Antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin may be a valuable treatment in severely immunocompromised, hospitalized, COVID-19 patients and should be considered when no monoclonal antibody therapies are available., Competing Interests: Potential conflicts of interest. F. S. and V. M. J. N. work at Sanquin Blood Supply Foundation. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2023
- Full Text
- View/download PDF
8. Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population.
- Author
-
Kockerols CCB, Janssen JJWM, Blijlevens NMA, Klein SK, Van Hussen-Daenen LGM, Van Gorkom GGY, Smit WM, Van Balen P, Biemond BJ, Cruijsen MJ, Corsten MF, Te Boekhorst PAW, Koene HR, Van Sluis GL, Cornelissen JJ, and Westerweel PE
- Subjects
- Humans, Pyrazoles therapeutic use, Niacinamide therapeutic use, Protein Kinase Inhibitors therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myeloid drug therapy
- Published
- 2023
- Full Text
- View/download PDF
9. Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10 9 /L to <100 × 10 9 /L) at baseline: the final analysis of EXPAND.
- Author
-
Guglielmelli P, Kiladjian JJ, Vannucchi AM, Duan M, Meng H, Pan L, He G, Verstovsek S, Boyer F, Barraco F, Niederwieser D, Pungolino E, Liberati AM, Harrison C, Roussou P, Wroclawska M, Karumanchi D, Sinclair K, Te Boekhorst PAW, and Gisslinger H
- Abstract
Background: Thrombocytopenia is a common feature of myelofibrosis (MF), a myeloproliferative neoplasm driven by dysregulated JAK/STAT signaling; however, pivotal trials assessing the efficacy of ruxolitinib (a JAK1/2 inhibitor) excluded MF patients with low platelet counts (<100 × 10
9 /L)., Objectives: Determination of the maximum safe starting dose (MSSD) of ruxolitinib was the primary endpoint, with long-term safety and efficacy as secondary and exploratory endpoints, respectively., Design: EXPAND (NCT01317875) was a phase 1b, open-label, ruxolitinib dose-finding study in patients with MF and low platelet counts (50 to <100 × 109 /L)., Methods: Patients were stratified according to baseline platelet count into stratum 1 (S1, 75 to <100 × 109 /L) or stratum 2 (S2, 50 to <75 × 109 /L). Previous analyses established the MSSD at 10 mg twice daily (bid); long-term results are reported here., Results: Of 69 enrolled patients, 38 received ruxolitinib at the MSSD (S1, n = 20; S2, n = 18) and are the focus of this analysis. The incidence of adverse events was consistent with the known safety profile of ruxolitinib, with thrombocytopenia (S1, 50%; S2, 78%) and anemia (S1, 55%; S2, 44%) the most frequently reported adverse events and no new or unexpected safety signals. Substantial clinical benefits were observed for patients in both strata: 50% (10/20) and 67% (12/18) of patients in S1 and S2, respectively, achieved a spleen response (defined as ⩾50% reduction in spleen length from baseline) at any time during the study., Conclusion: The final safety and efficacy results from EXPAND support the use of a 10 mg bid starting dose of ruxolitinib in patients with MF and platelet counts 50 to <100 × 109 /L., Registration: ClinicalTrials.gov NCT01317875., Competing Interests: Competing interests: PG reports payment of honoraria from Abbvie and Novartis; travel support from Abbvie, Novartis and Sanofi; participation in advisory boards from Abbvie and Novartis. JJK reports consulting fees from Abbvie and Novartis; payment of honoraria from AOP Orphan and Novartis; participation in advisory boards from BMS/Celgene and Incyte. AMV reports consulting fees from Abbvie, Blueprint, BMS/Celgene, Incyte, Novartis and Roche; payment of honoraria from Abbvie, BMS and Novartis. HM reports payment of honoraria from Novartis. LP reports payment of honoraria from Novartis. GH reports payment of honoraria from Novartis. SV reports research grants from AstraZeneca, Blueprint, Celgene, CTI BioPharma Corp., Genentech, Gilead, Incyte, Italpharma, Novartis, NS Pharma, Pharma Essentia, Promedior, Protagonist Therapeutics, Roche, Sierra Oncology; consulting fees from Celgene, Constellation, Incyte, Novartis, Pragmatist, Sierra. FBoyer reports consulting fees from Novartis. DN reports research funding from Daiichi; participation on speaker’s bureau from Amgen and Novartis; membership on an entity’s board of directors or advisory committees from Cellectis. AML reports institutional grants from Abbvie, Archigen, Beigene, Celgene, Fibrogen, GSK, Incyte, Janssen, Karyopharm, Morphosys, Novartis, Onconova, Oncopeptides, Pfizer, Roche, Sanofi, Servier, Takeda, Verastem; consulting fees from Incyte; payment of honoraria from Abbvie, BMS, Celgene, IQVIA, Janssen, Servier; travel support from Abbvie, BMS, Celgene, IQVIA, Janssen, Novartis, Roche, Sanofi, Takeda, Verastem; participation in advisory boards from Amgen and Servier. CH reports institutional grants from BMS/Celgene, Constellation Pharmaceuticals and Novartis; consulting fees from Novartis; payment of honoraria from Abbvie, AOP Orphan Pharmaceuticals, BMS/Celgene, CTI BioPharma Corp, Incyte, Janssen and Novartis; participation in advisory boards from AOP Orphan Pharmaceuticals, Celgene, Constellation Pharmaceuticals, CTI BioPharma Corp, Galecto, Geron, Incyte, Keros, Novartis, Promedior, Roche, Sierra Oncology. PR, MW, DK, and KS are employers and stockholders of Novartis. PAWTB reports participation in advisory boards from BMS/Celgene. HG reports research grants from AOP Orphan and Novartis; consulting fees from AOP Orphan, Myelopro, Novartis; payment of honoraria from AOP Orphan, BMS/Celgene, Janssen, Novartis. FBarraco, MD, and EP report no conflicts of interest., (© The Author(s), 2022.)- Published
- 2022
- Full Text
- View/download PDF
10. COVID-19 vaccination in patients with immune thrombocytopenia.
- Author
-
Visser C, Swinkels M, van Werkhoven ED, Croles FN, Noordzij-Nooteboom HS, Eefting M, Last-Koopmans SM, Idink C, Westerweel PE, Santbergen B, Jobse PA, Baboe F, Te Boekhorst PAW, Leebeek FWG, Levin MD, Kruip MJHA, and Jansen AJG
- Subjects
- COVID-19 Vaccines adverse effects, Female, Humans, Male, Middle Aged, Vaccination adverse effects, COVID-19 complications, COVID-19 epidemiology, COVID-19 prevention & control, Purpura, Thrombocytopenic, Idiopathic complications, Purpura, Thrombocytopenic, Idiopathic epidemiology, Thrombocytopenia complications, Thrombocytopenia etiology
- Abstract
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder that is characterized by low platelet count and increased bleeding risk. COVID-19 vaccination has been described as a risk factor for de novo ITP, but the effects of COVID-19 vaccination in patients with ITP are unknown. We aimed to investigate the effects of COVID-19 vaccination in patients with ITP on platelet count, bleeding complications, and ITP exacerbation (≥50% decline in platelet count, or nadir platelet count < 30 × 109/L with a >20% decrease from baseline, or use of rescue therapy). Platelet counts in patients with ITP and healthy controls were collected immediately before and 1 and 4 weeks after the first and second vaccinations. Linear mixed-effects modeling was applied to analyze platelet counts over time. We included 218 patients with ITP (50.9% female; mean age, 55 years; and median platelet count, 106 × 109/L) and 200 healthy controls (60.0% female; mean age, 58 years; median platelet count, 256 × 109/L). Platelet counts decreased by 6.3% after vaccination. We did not observe any difference in decrease between the groups. Thirty patients with ITP (13.8%; 95% confidence interval [CI], 9.5-19.1) had an exacerbation and 5 (2.2%; 95% CI, 0.7-5.3) suffered from a bleeding event. Risk factors for ITP exacerbation were platelet count < 50 × 109/L (odds ratio [OR], 5.3; 95% CI, 2.1-13.7), ITP treatment at time of vaccination (OR, 3.4; 95% CI, 1.5-8.0), and age (OR, 0.96 per year; 95% CI, 0.94-0.99). Our study highlights the safety of COVID-19 vaccination in patients with ITP and the importance of the close monitoring of platelet counts in a subgroup of patients with ITP. Patients with ITP with exacerbation responded well on therapy., (© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
11. Late excess mortality in essential thrombocythemia: a population-based study in the Netherlands, 2001-2018.
- Author
-
Posthuma TSM, Visser O, Te Boekhorst PAW, and Dinmohamed AG
- Subjects
- Adolescent, Adult, Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasms pathology, Netherlands epidemiology, Prognosis, Retrospective Studies, Risk Factors, Survival Rate, Thrombocythemia, Essential chemically induced, Thrombocythemia, Essential epidemiology, Thrombocythemia, Essential pathology, Time Factors, Young Adult, Antineoplastic Combined Chemotherapy Protocols adverse effects, Neoplasms drug therapy, Thrombocythemia, Essential mortality
- Published
- 2022
- Full Text
- View/download PDF
12. Therapeutic plasma exchange for anticoagulant-refractory antiphospholipid syndrome with severe ischemic and necrotic skin lesions: A case series.
- Author
-
Croles FN, Te Boekhorst PAW, Leebeek FWG, and Jansen AJG
- Subjects
- Aged, Antibodies, Anticardiolipin blood, Antiphospholipid Syndrome pathology, Antiphospholipid Syndrome therapy, Female, Glucocorticoids therapeutic use, Heparin, Low-Molecular-Weight, Humans, Immunoglobulin G immunology, Immunoglobulin M immunology, Ischemia pathology, Lupus Coagulation Inhibitor immunology, Male, Middle Aged, Necrosis pathology, Necrosis therapy, Skin Diseases pathology, Thrombosis immunology, beta 2-Glycoprotein I immunology, Anticoagulants chemistry, Antiphospholipid Syndrome immunology, Ischemia therapy, Plasma Exchange methods, Skin Diseases therapy
- Abstract
Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by clinical findings including thrombosis and/or obstetric complication and laboratory findings, e.g. ≥1 positive antiphospholipid antibodies (aPL) (lupus anticoagulant, anticardiolipin IgG/IgM and/or anti-β2-glycoprotein IgG/IgM). A rare APS clinical entity is severe necrosis which is difficult to treat and often does not respond to anticoagulant therapy. Three consecutive patients with primary or secondary APS who presented with necrotic skin lesions secondary to APS were treated with therapeutic plasma exchange (TPE), glucocorticoids and low-molecular-weight heparin. All patients had a rapid-onset, either full or significant recovery of their APS-related necrotic lesions. Upon treatment, one patients showed resolution of lupus anticoagulant. Two patients had a decrease of at least 88 % in aPL titers after the initial treatment, and were kept on TPE maintenance every 5-6 weeks. None of the patients experienced significant side effects of the TPE. This is the first case series showing the clinical benefits of TPE in patients with ischemic and necrotic skin lesions due to severe anticoagulant-refractory vascular APS., (Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
13. Survival in Primary Myelofibrosis: A Population-based Analysis in the Netherlands.
- Author
-
Slot S, Dinmohamed AG, Visser O, Te Boekhorst PAW, and Zweegman S
- Published
- 2021
- Full Text
- View/download PDF
14. Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells.
- Author
-
Mout L, van Dessel LF, Kraan J, de Jong AC, Neves RPL, Erkens-Schulze S, Beaufort CM, Sieuwerts AM, van Riet J, Woo TLC, de Wit R, Sleijfer S, Hamberg P, Sandberg Y, Te Boekhorst PAW, van de Werken HJG, Martens JWM, Stoecklein NH, van Weerden WM, and Lolkema MP
- Subjects
- Aged, Aged, 80 and over, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, DNA, Neoplasm genetics, Genetic Heterogeneity, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplastic Cells, Circulating drug effects, Neoplastic Cells, Circulating metabolism, Organoids, Prospective Studies, Prostatic Neoplasms blood, Prostatic Neoplasms genetics, Prostatic Neoplasms therapy, Treatment Outcome, Tumor Cells, Cultured, Cell Separation, Leukapheresis, Neoplastic Cells, Circulating pathology, Prostatic Neoplasms pathology
- Abstract
Background: Circulating tumour cell (CTC)-derived organoids have the potential to provide a powerful tool for personalised cancer therapy but are restrained by low CTC numbers provided by blood samples. Here, we used diagnostic leukapheresis (DLA) to enrich CTCs from patients with metastatic prostate cancer (mPCa) and explored whether organoids provide a platform for ex vivo treatment modelling., Methods: We prospectively screened 102 patients with mPCa and performed DLA in 40 patients with ≥5 CTCs/7.5 mL blood. We enriched CTCs from DLA using white blood cell (WBC) depletion alone or combined with EpCAM selection. The enriched CTC samples were cultured in 3D to obtain organoids and used for downstream analyses., Results: The DLA procedure resulted in a median yield of 5312 CTCs as compared with 22 CTCs in 7.5 mL of blood. Using WBC depletion, we recovered 46% of the CTCs, which reduced to 12% with subsequent EpCAM selection. From the isolated and enriched CTC samples, organoid expansion succeeded in 35%. Successful organoid cultures contained significantly higher CTC numbers at initiation. Moreover, we performed treatment modelling in one organoid cell line and identified substantial tumour heterogeneity in CTCs using single cell DNA sequencing., Conclusions: DLA is an efficient method to enrich CTCs, although the modest success rate of culturing CTCs precludes large scale clinical application. Our data do suggest that DLA and subsequent processing provides a rich source of viable tumour cells. Therefore, DLA offers a promising alternative to biopsy procedures to obtain sufficient number of tumour cells to study sequential samples in patients with mPCa., Trial Registration Number: NL6019., Competing Interests: Conflict of interest statement Ronald de Wit has an advisory role and/or received speaker fees from; Sanofi, Merck, Lilly, Roche, Bayer, Janssen, Clovis and research funding (Institutional); Sanofi, Bayer. Stefan Sleijfer is the chair of Center for Personalised Cancer Treatment (CPCT), chair of Dutch Science Agenda Personalized Medicine and SkylineDx. Harmen van de Werken has stock and/or other ownership interests in Cergentis and has received honoraria from Bayer. Martijn Lolkema has an advisory role and/or received speaker fees from; Incyte, Amgen, Janssen Cilag B.V., Bayer, Servier, Roche, Pfizer Sanofi Aventis Netherlands BV, Astellas and has received (Institutional) research funding from Sanofi, JnJ, Merck and Astellas. Wytske van Weerden has received (Institutional) research funding from —Sanofi, Janssen Pharmaceuticals and Bayer.Rui P.L. Neves has an advisory role and/or received speaker fees from; Menarini Silicon Biosystems, Thermo Fisher Scientific, Terumo BCT.Nikolas Stoecklein has received remunerations from Menarini Silicon Biosystems., (Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
15. A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms.
- Author
-
Hamulyák EN, Daams JG, Leebeek FWG, Biemond BJ, Te Boekhorst PAW, Middeldorp S, and Lauw MN
- Subjects
- Anticoagulants therapeutic use, Fibrinolytic Agents therapeutic use, Humans, Myeloproliferative Disorders complications, Myeloproliferative Disorders drug therapy, Neoplasms drug therapy, Thrombosis drug therapy, Venous Thromboembolism drug therapy, Venous Thromboembolism etiology, Venous Thromboembolism prevention & control
- Abstract
Patients with myeloproliferative neoplasms (MPNs), polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have an increased risk of thrombosis. Risk of recurrent thrombosis can be reduced with antithrombotic therapy and/or cytoreduction, but the optimal long-term management in patients with MPN with a history of venous thromboembolism (VTE) is unknown, and clinical practice is heterogeneous. We performed a systematic review and meta-analysis of randomized trials and observational studies evaluating anticoagulant and/or antiplatelet therapy, with or without cytoreduction, in MPN patients with a history of VTE. A total of 5675 unique citations were screened for eligibility. No randomized trials were identified. Ten observational studies involving 1295 patients with MPN were included in the analysis. Overall, 23% had an arterial or recurrent venous thrombotic event on follow-up. The recurrence risk was lowest for patients on oral anticoagulation plus cytoreduction (16%); 55 of 313 (18%) with vitamin K antagonists (VKA) and 5 of 63 (8%) with direct oral anticoagulants (DOACs). In 746 analyzed patients, the risk of recurrent VTE ranged up to 33% (median 13%) and was low in 63 DOAC plus cytoreduction-treated patients (3.2%). All types of antithrombotic treatments were associated with a lower risk of recurrent VTE when combined with cytoreduction. Most studies had a high risk of bias, whereas clinical and statistical heterogeneity led to inconsistent and imprecise findings. In summary, evidence on the optimal antithrombotic treatment of VTE in patients with MPN is based on observational studies only with low certainty for all strategies. Our data suggest that a combination of anticoagulation and cytoreduction may provide the lowest recurrence risk., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
16. COVID-19-associated immune thrombocytopenia.
- Author
-
Bomhof G, Mutsaers PGNJ, Leebeek FWG, Te Boekhorst PAW, Hofland J, Croles FN, and Jansen AJG
- Subjects
- Aged, Betacoronavirus, COVID-19, Coronavirus Infections therapy, Female, Humans, Male, Middle Aged, Pandemics, Pneumonia, Viral therapy, Purpura, Thrombocytopenic, Idiopathic therapy, SARS-CoV-2, Coronavirus Infections complications, Pneumonia, Viral complications, Purpura, Thrombocytopenic, Idiopathic etiology
- Published
- 2020
- Full Text
- View/download PDF
17. Results of the prematurely terminated TEMPLE randomized controlled trial in patients with myelodysplastic syndrome: liberal versus restrictive red blood cell transfusion threshold.
- Author
-
Jansen AJG, van den Bosch J, Te Boekhorst PAW, Schipperus MR, and Beckers EAM
- Subjects
- Humans, Erythrocyte Transfusion methods, Myelodysplastic Syndromes therapy, Randomized Controlled Trials as Topic
- Published
- 2020
- Full Text
- View/download PDF
18. Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life: Results in Dutch Patients and Review of the Literature.
- Author
-
Slot S, Raymakers RAP, Schaap N, Span LFR, Koene HR, Kersting S, Te Boekhorst PAW, Westerman M, Schouten HC, and Zweegman S
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Janus Kinase 2 metabolism, Male, Middle Aged, Netherlands, Nitriles, Platelet Count, Primary Myelofibrosis blood, Pyrazoles adverse effects, Pyrimidines, Retrospective Studies, Thrombocytopenia blood, Thrombocytopenia chemically induced, Janus Kinase 2 antagonists & inhibitors, Primary Myelofibrosis drug therapy, Pyrazoles therapeutic use, Thrombocytopenia diagnosis
- Abstract
Background: Ruxolitinib is an approved treatment for myelofibrosis patients, but data regarding patients with baseline thrombocytopenia are limited. The EXPAND study recently suggested tolerability of ruxolitinib, with a maximum starting dose of 10 mg 2 times a day (BID). However, the small sample size and vigorous follow-up in this trial hamper direct translation of these results to routine practice., Patients and Methods: We report retrospective data on Dutch ruxolitinib-treated myelofibrosis patients, focusing on those with baseline thrombocytopenia. Additionally, we reviewed current literature regarding ruxolitinib treatment in this subgroup., Results: In our cohort, 12 of 119 patients had a baseline platelet count of < 100 × 10
9 /L. Spleen responses at a mean treatment duration of 25 weeks were documented in 1 of 6 and 15 of 47 patients with and without baseline thrombocytopenia, respectively. Despite a high rate of grade 3 or higher thrombocytopenia in thrombocytopenic versus nonthrombocytopenic patients (42% vs. 15%), no grade 3 or higher hemorrhage was reported. Median doses in thrombocytopenic patients were 15 and 10 mg BID at the start and after 12 weeks of treatment, respectively. Additionally, 238 thrombocytopenic patients were identified in the available literature, of whom 59 were treated in routine practice. Incidences of severe thrombocytopenia reported separately for patients with baseline thrombocytopenia were 30% to 59% (grade 3 or higher) and 4% to 60% (grade 4). Severe bleeding, pooled across our data and evaluable studies, occurred in 2.4%., Conclusion: Ruxolitinib treatment appears to be safe for patients with platelet counts of 50 to 100 × 109 /L in real-life practice. We did not find any reason to discourage a starting dose of 10 mg BID in this subgroup., (Copyright © 2019 Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
19. New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia.
- Author
-
Westerweel PE, Te Boekhorst PAW, Levin MD, and Cornelissen JJ
- Abstract
Current treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI) is effective in many patients, but is not curative and frequently limited by intolerance or resistance. Also, treatment free remission is a novel option for CML patients and requires reaching a deep molecular remission, which is not consistently achieved with TKI monotherapy. Together, multiple unmet clinical needs remain and therefore the continued need to explore novel treatment strategies. With increasing understanding of CML biology, many options have been explored and are under investigation. This includes the use asciminib as first in class inhibitor targeting the myristoyl pocket of BCR-ABL, combination treatments with established non-TKI drugs such as interferon and drugs with novel targets relevant to CML biology such as gliptins and thiazolidinediones. Together, an overview is provided of treatment strategies in development for CML beyond current TKI monotherapy.
- Published
- 2019
- Full Text
- View/download PDF
20. EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis.
- Author
-
Vannucchi AM, Te Boekhorst PAW, Harrison CN, He G, Caramella M, Niederwieser D, Boyer-Perrard F, Duan M, Francillard N, Molloy B, Wroclawska M, and Gisslinger H
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Male, Maximum Tolerated Dose, Middle Aged, Nitriles, Primary Myelofibrosis pathology, Prognosis, Pyrimidines, Young Adult, Primary Myelofibrosis drug therapy, Protein Kinase Inhibitors therapeutic use, Pyrazoles therapeutic use
- Abstract
EEXPAND (phase Ib, dose-finding study) evaluated the starting dose of ruxolitinib in patients with myelofibrosis with baseline platelet counts of 50-99×10
9 /L. The study consisted of dose-escalation and safety-expansion phases. Based on the baseline platelet counts, patients were assigned to stratum 1 (75-99×109 /L) or stratum 2 (50-74×109 /L), with the primary objective of determining the maximum safe starting dose (MSSD); key secondary objectives included safety and efficacy. At week 48 data cutoff (stratum 1, n=44; stratum 2, n=25), 24.6% (17 out of 69) of patients were still receiving treatment. The MSSD was established as ruxolitinib 10 mg twice daily in both strata. Thrombocytopenia [grade 4 (stratum 1, n=1; stratum 2, n=2)] was the only reported dose-limiting toxicity (study drug related) at 10 mg twice daily. In the MSSD cohort (stratum 1, n=20; stratum 2, n=18), adverse events (regardless of study drug relationship) led to treatment discontinuation in 15.0% and 33.3% of patients in stratum 1 and stratum 2, respectively, and dose adjustment/interruption in 45.0% and 66.7% of patients in stratum 1 and stratum 2, respectively. Three cases of on-treatment deaths were reported at the MSSD. Spleen response was achieved at week 48 in 33.3% and 30.0% of patients in stratum 1 and stratum 2, respectively. Improvements in the Total Symptom Score were also observed. In this study, ruxolitinib demonstrated acceptable tolerability in both the strata at the MSSD of 10 mg twice daily. (Registered at: clinicaltrials.gov identifier: 01317875 )., (Copyright© 2019 Ferrata Storti Foundation.)- Published
- 2019
- Full Text
- View/download PDF
21. Patchy hematopoiesis mimicking bone metastasis.
- Author
-
Cornelisse AC and Te Boekhorst PAW
- Subjects
- Aged, Bone Marrow diagnostic imaging, Bone Marrow Diseases diagnostic imaging, Bone Neoplasms diagnostic imaging, Bone Neoplasms secondary, Diagnosis, Differential, Female, Hematopoiesis, Humans, Tomography, X-Ray Computed methods, Bone Marrow pathology, Bone Marrow Diseases diagnosis, Bone Neoplasms diagnosis
- Published
- 2018
- Full Text
- View/download PDF
22. Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia.
- Author
-
Bouillon AS, Ventura Ferreira MS, Awad SA, Richter J, Hochhaus A, Kunzmann V, Dengler J, Janssen J, Ossenkoppele G, Westerweel PE, Te Boekhorst PAW, Mahon FX, Hjorth-Hansen H, Isfort S, Fioretos T, Hummel S, Schemionek M, Wilop S, Koschmieder S, Saußele S, Mustjoki S, Beier F, and Brümmendorf TH
- Subjects
- Adult, Aged, Female, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive diagnosis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Male, Middle Aged, Protein Kinase Inhibitors administration & dosage, Hematopoietic Stem Cells metabolism, Leukemia, Myelogenous, Chronic, BCR-ABL Positive metabolism, Telomere Homeostasis
- Abstract
Telomere length (TL) in peripheral blood (PB) cells of patients with chronic myeloid leukemia (CML) has been shown to correlate with disease stage, prognostic scores, response to therapy, and disease progression. However, due to considerable genetic interindividual variability, TL varies substantially between individuals, limiting its use as a robust prognostic marker in individual patients. Here, we compared TL of BCR-ABL
- , nonleukemic CD34+ CD38- hematopoietic stem cells (HSC) in the bone marrow of CML patients at diagnosis to their individual BCR-ABL+ leukemic stem cell (LSC) counterparts. We observed significantly accelerated telomere shortening in LSC compared with nonleukemic HSC. Interestingly, the degree of LSC telomere shortening was found to correlate significantly with the leukemic clone size. To validate the diagnostic value of nonleukemic cells as internal controls and to rule out effects of tyrosine kinase inhibitor (TKI) treatment on these nontarget cells, we prospectively assessed TL in 134 PB samples collected in deep molecular remission after TKI treatment within the EURO-SKI study (NCT01596114). Here, no significant telomere shortening was observed in granulocytes compared with an age-adjusted control cohort. In conclusion, this study provides proof of principle for accelerated telomere shortening in LSC as opposed to HSC in CML patients at diagnosis. The fact that the degree of telomere shortening correlates with leukemic clone's size supports the use of TL in leukemic cells as a prognostic parameter pending prospective validation. TL in nonleukemic myeloid cells seems unaffected even by long-term TKI treatment arguing against a reduction of telomere-mediated replicative reserve in normal hematopoiesis under TKI treatment., (© 2018 by The American Society of Hematology.)- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.